Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Invictus MD Strategies Corp IVITF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.


GREY:IVITF - Post by User

Invictus MD Strategies Corp
Bullboard Posts
User Avatar Image
(2)
•••
Comment by makinprofiton May 30, 2018 9:13am
111 Views
Post# 28098082

RE:RE:Canaccord Genuity Report - Spec Buy, $3.00 Price Target

RE:RE:Canaccord Genuity Report - Spec Buy, $3.00 Price Target@doubleLs--my thoughts echo yours. Sure would love to see $3 soon though. And higher.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities